CV Sciences (0HRT) AI Stock Analysis

0 Followers

CV Sciences

(LSE:0HRT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improving operating efficiencyHigher gross margin combined with lower operating expenses indicates that CV Sciences is improving cost discipline despite weaker sales. If sustained, this operating leverage can support profitability, reduce cash burn, and improve the resilience of the PlusCBD business over the next several quarters.

Negative Factors

Sustained revenue contractionThe persistent decline in revenue indicates that CV Sciences is not yet translating its product activity into durable top-line growth. Continued contraction can reduce scale benefits, weaken retailer momentum, and make it harder for fixed operating costs to be absorbed across the business.

CV Sciences (0HRT) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $2.01M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -1.0
Beta (1Y): -0.28
Revenue Growth: -12.88%
EPS Growth: -8.75%
Country: UK
Employees: 43
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

CV Sciences Business Overview & Revenue Model

Company Description

CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division fo...

CV Sciences Earnings Call Summary

Earnings Call Date:Aug 17, 2026(Q2-2026)|% Change Since:0.00%|Next Earnings Date:May 16, 2022

Earnings Call SentimentNeutral

The call presented a balanced picture: the company is making meaningful progress on cost reductions, working capital management and product/brand expansion (including a growing non‑cannabinoid line and DTC efforts) and has achieved modest positive operating cash flow. However, material top-line pressure (revenue down 7% QoQ and 17% YoY; unit sales down 15%), widening GAAP net loss ($0.8M) and a low cash balance (~$0.3M) are significant headwinds. Regulatory uncertainty remains an important risk. Overall, positives (cost discipline, product launches, near cash‑flow breakeven) are counterbalanced by substantial revenue and liquidity challenges.

Positive Updates

Revenue Resilience

Generated revenue of $3.0 million in Q2 2026; while down 7% sequentially (from $3.2M) and 17% year-over-year, management emphasized resilience in a constrained operating environment.

Negative Updates

Top-Line Decline and Volume Pressure

Revenue decreased 7% sequentially and 17% year-over-year to $3.0 million, driven primarily by a 15% decline in unit sales—reflecting continued category contraction and competitive pressure.

Company Guidance

Management guided that the company will prioritize scaling and profitable growth by expanding non‑cannabinoid +PlusHLTH product launches and select international expansion via Cultured Foods while continuing strict cost and working‑capital discipline to drive margins and cash flow. Key metrics referenced: Q2 revenue of $3.0M (down 7% sequential, 17% YoY; unit sales down 15%), gross margin 48.6% (48.9% in Q1; 50.9% year‑ago), SG&A $1.7M (down ~7.9% sequential/~10% YoY), adjusted EBITDA loss $0.1M (flat vs Q1), operating loss $0.3M, net loss $0.8M, positive operating cash flow of ~ $20k in Q2 (also positive in Q1), cash ≈ $0.3M, inventory ≈ $4.0M (vs $4.1M year‑end), and convertible note fair value $1.0M after ~ $0.7M of conversions — with an aim to reach sustainable positive operating cash flow and to remain flexible pending regulatory timing changes (potential delay of Nov 12, 2026 provisions to Dec 11, 2026).

CV Sciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0HRT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXHL	43Neutral	$25.34M	-2.94	-12.40%	―	-100.00%	96.25%
YCBD	43Neutral	$4.40M	-1.22	-34.25%	―	10.01%	95.01%
COSM	39Underperform	$20.89M	-4.91	-118.89%	―	33.82%	34.05%
IMCC	29Underperform	$911.06K	-0.02	841.81%	―	-11.91%	-285.26%

* Healthcare Sector Average

Performance Comparison

GB:0HRT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0HRT	CV Sciences	0.02	-0.03	-60.00%
YCBD	Cbdmd INc	0.37	-0.23	-37.67%
COSM	Cosmos Holdings	3.24	-10.76	-76.86%
IMCC	Im Cannabis Corp	0.57	-29.39	-98.10%
IXHL	Incannex Healthcare Limited Sponsored ADR	1.97	-8.21	-80.65%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CV Sciences AI Stock Analysis